Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Introduction and objectives: Transcatheter aortic valve implantation (TAVI) was first
introduced in 2007 as an alternative to open heart surgery to treat patients with severe …

Background Increasing reports suggest the safe use of direct oral anticoagulants (DOACs) in
electrical cardioversion. The aim of this study was to assess the trends and 30-day outcomes …

Background/Objective AUGUSTUS trial demonstrated that, for patients with atrial fibrillation
(AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary …

Introducción y objetivos: El implante percutáneo de válvula aórtica (TAVI) se introdujo en
2007 como una alternativa a la cirugía a corazón abierto para tratar a pacientes con …

Stroke is a major cause of morbidity in industrialized countries, representing 8% of total
deaths across Europe in 2017. It is also a very costly disorder, frequently caused by atrial …

The relevant cost-effectiveness study reports economic terms in the currency units of each
country at a certain time unit, so that currency conversion is needed for the standardization …

Atrial fibrillation (AF) is associated with a five-fold increase in the risk of thromboembolic
events (stroke/systemic embolism). When initiated in individuals at risk of a thromboembolic …

El ictus continúa siendo la segunda causa de mortalidad y la tercera causa de discapacidad
a nivel mundial, con una incidencia y prevalencia mayor en mujeres, según las …